司美替尼治疗成人1型神经纤维瘤病伴症状性不可手术丛状神经纤维瘤的疗效与安全性(KOMET):一项多中心、国际、随机、安慰剂对照、平行、双盲3期研究
KOMET是一项进行中的多中心、国际、随机、安慰剂对照、3期双盲试验,纳入184例成人1型神经纤维瘤病伴丛状神经纤维瘤患者,145例随机分配至司美替尼25 mg/m²口服每日两次(28天为一周期)或安慰剂,安慰剂组在确认影像学进展或第12周期结束时交叉至司美替尼。主要终点为至第16周期由独立中心按REiNS标准确认的客观缓解率(部分或完全缓解),司美替尼组20%(14/71,95%CI 11.2–30.9)vs 安慰剂组5%(4/74,95%CI 1.5–13.3),p=0.011,中位起效时间3.7个月。基线慢性疼痛强度评分≥3分的患者中,第12周期评分较基线的下降在司美替尼组大于安慰剂组(最小二乘均值[SE] -2.0[0.30],-2.6至-1.4 vs -1.3[0.29],-1.8至-0.7;p=0.070),未达统计学显著,但为有临床意义的改善;PlexiQoL总分第12周期较基线的变化组间无显著差异(最小二乘均值差[SE] -0.1[0.59],-1.2至1.1)。不良事件与司美替尼已知安全性特征一致。
要点
- 至第16周期客观缓解率:司美替尼组20%(14/71,95%CI 11.2–30.9)vs 安慰剂组5%(4/74,95%CI 1.5–13.3),p=0.011。
- 司美替尼起效迅速,中位起效时间3.7个月。
- 基线慢性疼痛强度评分≥3分者第12周期评分下降:司美替尼组最小二乘均值-2.0(SE 0.30,95%CI -2.6至-1.4)vs 安慰剂组-1.3(SE 0.29,95%CI -1.8至-0.7),p=0.070,未达统计学显著,但为有临床意义的改善。
- PlexiQoL总分第12周期较基线变化组间无显著差异(最小二乘均值差-0.1,SE 0.59,95%CI -1.2至1.1)。
- 不良事件与司美替尼已知安全性特征一致,未发现新的安全性问题。
适用人群与场景
- 成人1型神经纤维瘤病伴症状性、不可手术的丛状神经纤维瘤患者。
诊断标准与关键阈值
- 客观缓解由独立中心按Response Evaluation in Neurofibromatosis and Schwannomatosis(REiNS)标准评定,为确认的部分缓解或完全缓解。
处置流程与药物剂量
- 司美替尼25 mg/m²口服,每日两次,28天为一周期。
- 安慰剂组在确认影像学进展或第12周期结束时交叉至司美替尼。
研究设计与关键结果
- 多中心、国际、随机、安慰剂对照、平行、双盲3期试验,184例入组,145例随机分配至司美替尼(n=71)或安慰剂(n=74)。
- 主要终点至第16周期客观缓解率:司美替尼组20%(14/71,95%CI 11.2–30.9)vs 安慰剂组5%(4/74,95%CI 1.5–13.3),p=0.011。
- 司美替尼中位起效时间3.7个月。
- 基线慢性疼痛强度评分≥3分者第12周期评分较基线下降:司美替尼组最小二乘均值-2.0(SE 0.30,95%CI -2.6至-1.4)vs 安慰剂组-1.3(SE 0.29,95%CI -1.8至-0.7),p=0.070,未达统计学显著。
- PlexiQoL总分第12周期较基线变化组间无显著差异(最小二乘均值差-0.1,SE 0.59,95%CI -1.2至1.1)。
- 不良事件与司美替尼已知安全性特征一致。
证据类型、等级与局限
- 证据类型:多中心、国际、随机、安慰剂对照、平行、双盲3期试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,第16周期肿瘤体积缩小、慢性疼痛与刺痛减轻、镇痛药使用减少及疼痛干扰下降均优于安慰剂,表明司美替尼可有效治疗成人1型神经纤维瘤病相关丛状神经纤维瘤。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Currently, no worldwide approved therapies exist for adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas. The KOMET study aimed to evaluate selumetinib (ARRY-142886, AZD6244) efficacy and safety in this population.
METHODS: This ongoing multicentre, international, randomised, placebo-controlled, phase 3, parallel, double-blind trial randomly assigned adults with NF1-plexiform neurofibroma 1:1 to 28-day cycles of oral selumetinib 25 mg/m2 twice daily, or placebo with crossover to selumetinib at confirmed radiological progression or the end of cycle 12. The primary endpoint was objective response rate (confirmed partial or complete response) established by use of independent central review per Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) criteria by cycle 16 (selumetinib vs placebo). This study (KOMET) is registered with ClinicalTrials.gov, NCT04924608 and is ongoing.
FINDINGS: Overall, of 184 participants enrolled, 145 adults were randomly assigned to selumetinib (n=71) or placebo (n=74). Selumetinib led to a rapid response (median 3·7 months), with an objective response rate of 20% (n=14/71; 95% CI 11·2 to 30·9) by cycle 16 versus 5% (n=4/74; 1·5 to 13·3) with placebo (p=0·011). Participants with baseline chronic pain intensity scores of at least 3 had a greater reduction in score at cycle 12 with selumetinib versus placebo (least-squares mean [SE] -2·0 [0·30] -2·6 to -1·4, vs -1·3 [0·29] -1·8 to -0·7; p=0·070), although this did not reach significance; and a clinically meaningful improvement from baseline. Change from baseline to cycle 12 in PlexiQoL total scores between treatment groups was not significant (least-squares mean difference [SE] -0·1 [0·59]; -1·2 to 1·1). Adverse events were consistent with the known selumetinib safety profile.
INTERPRETATION: In the first international, randomised, placebo-controlled trial in adults with NF1-plexiform neurofibromas, selumetinib achieved a significant objective response rate versus placebo. No new safety concerns were identified. The observations of reduction in tumour volume by cycle 16, reduction in chronic and spike pain, reduction in analgesia, and decrease in pain interference over placebo show that selumetinib is effective at treating plexiform neurofibromas in adults with NF1.
FUNDING: AstraZeneca as part of an alliance between AstraZeneca and Merck Sharp & Dohme, a subsidiary of Merck, Rahway, NJ, USA.
参考来源
- Chen AP, Coyne GO, Wolters PL, et al. Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. Lancet. 2025. PMID: 40473450. doi:10.1016/S0140-6736(25)00986-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。